Instil Bio, Inc.

NASDAQ:TIL

Biotechnology

Healthcare
$7.45 +0.13%

+$0.01 today

Market cap
$50.53M
Beta
1.91
P/E (TTM)
-1.1
EPS (TTM)
-$6.99
52W Low $5.67High $33.83

Volume 0.02M

Average 0.03M

TIL Net Income

Bottom-line profit after all expenses, interest, and taxes.

Instil Bio, Inc.NASDAQ: TIL

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$4.2M, compared with -$28.2M a year earlier. Trailing-twelve-month net income was -$47.38M.

Context

  • Net income grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 2 analysts of -$7.8M (+89.1%) for the fiscal year ending Dec 2026, a step up from the +3.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.2M+48.7% QoQ
Last fiscal yearDec 2025
-$71.37M+3.7% YoY
LTMMar 2026
-$47.38M+39.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+85.1%+88.9%+3.8 pp
1 year+3.7%+89.1%+85.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(71.37M) USD
Year-over-year change
+3.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How TIL compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +39.3% is the 3rd highest of 9, against a peer median of -8.1%.
TIL Competitors
Net Income for TIL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ONCYOncolytics Biotech Inc.LTM Mar 2026-CA$35.52M CAD-20.2%——
IFRXInflaRx N.V.LTM Mar 2026-€42.91M EUR+4.0%—146303.9%
TILInstil Bio, Inc.LTM Mar 2026-$47.38M USD+39.3%——
STTKShattuck Labs, Inc.LTM Mar 2026-$49.87M USD+29.4%—4987.4%
MGNXMacroGenics, Inc.LTM Mar 2026-$70.36M USD-26.1%—44.8%
PLRXPliant Therapeutics, Inc.LTM Mar 2026-$113.22M USD+48.4%——
WHWKWhitehawk Therapeutics IncLTM Mar 2026-$115.81M USD-519.4%——
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026-$124.13M USD+44.6%——
SRZNSurrozen, Inc.LTM Mar 2026-$342.56M USD-319.3%—4571.1%
Peer median (excluding TIL) —-8.1%—4779.3%

Competitors are the stored peer set for TIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue05.99M00534K
Gross Profit0(5.99M)00(534K)
Gross Margin—————
Research & Development107.25M141.06M39.6M11.84M10M
Selling, General & Admin51.31M62.24M47.55M44.21M27.22M
Operating Expenses155.56M200.18M159.17M73.54M52.37M
Depreciation & Amortization2.75M5.99M4.76M3.61M534K
EBITDA(152.51M)(217.38M)(147.12M)(62.53M)(65.01M)
EBITDA Margin—————
Operating Income(155.56M)(206.17M)(159.17M)(73.54M)(52.91M)
Operating Margin—————
Interest Income80K3.66M8.87M6.99M3.86M
Interest Expense01.88M5.21M8.99M5.83M
Other Income / Expenses(1.2M)(19.08M)3.08M(594K)(18.47M)
Income Before Tax(156.76M)(225.25M)(156.09M)(74.14M)(71.37M)
Pre-Tax Margin—————
Income Tax Expense39K(2.07M)000
Net Income(156.79M)(223.18M)(156.09M)(74.14M)(71.37M)
Net Margin—————
EPS (Basic)(29.60)(34.46)(24.00)(11.39)(10.70)
EPS (Diluted)(29.60)(34.46)(24.00)(11.39)(10.70)
Weighted Avg Shares5.3M6.48M6.5M6.51M6.67M
Weighted Avg Shares (Diluted)5.3M6.48M6.5M6.51M6.67M

Instil Bio, Inc.

NASDAQ:TIL

Intrinsic Alpha fair value

Locked

Current Price

$7.45

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.